ACADIA Pharmaceuticals is dedicated to advancing neuroscience through the development of innovative therapies aimed at addressing significant unmet medical needs. The company has pioneered the first and only FDA-approved treatments for hallucinations and delusions associated with Parkinson’s disease psychosis and Rett syndrome. Their current pipeline includes clinical-stage developments targeting conditions such as Alzheimer’s disease psychosis, Prader-Willi syndrome, and various neuropsychiatric symptoms. ACADIA's commitment to elevating life through science is evident in their focus on rare diseases and their ongoing efforts to create effective solutions for patients suffering from these challenging conditions.

The company’s product pipeline showcases a range of investigational agents and FDA-approved medications, including NUPLAZID® (pimavanserin) for Parkinson’s disease psychosis and DAYBUE™ (trofinetide) for Rett syndrome. ACADIA is also exploring multiple antisense oligonucleotide (ASO) programs in collaboration with Stoke Therapeutics, aimed at developing RNA-based medicines for severe genetic neurodevelopmental diseases. Their strategic focus on both established and emerging therapies reflects a robust commitment to scientific innovation and patient care, ensuring that they remain at the forefront of neuroscience advancements.

United States

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Central Nervous System (CNS)

Nervous System Diseases

ACADIA Pharmaceuticals

Parkinson's disease

Pimavanserin is a proprietary small molecule currently being researched and developed for dementia-related psychosis. Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors that are thought to play an important role in dementia-related psychosis.

NUPLAZID® (pimavanserin) (serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors) 

Rett syndrome

Trofinetide is a novel synthetic analog of the amino‐terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

DAYBUE™ (Trofinetide )

Prader-Willi syndrome

An intranasal formulation of carbetocin. Carbetocin has improved drug qualities relative to oxytocin, including an extended duration of action and greater specificity for the oxytocin receptors compared to vasopressin receptors which could provide meaningful efficacy with an attractive safety profile in patients with PWS.8 For the treatment of Prader-Willi syndrome specifically, a central nervous system disorder, an intranasal formulation of carbetocin was developed, which provides direct delivery of the drug to the brain, greatly reducing systemic exposure and the potential for side effects.

ACP-101 (intranasal carbetocin)

Alzheimer's disease

ACP-204

Essential tremor

ACP-711 (SAN711)

Pain

Post operative acute pain

ACP-044 is a novel, first-in-class, orally administered, non-opioid analgesic. The mechanism of action is thought to interrupt multiple pain pathways and sensitization of neurons to pain, by accelerating the decomposition of peroxynitrite, a by-product of tissue damage.

ACP-044 

Schizophrenia

Pimavanserin is a proprietary small molecule currently being researched and developed for dementia-related psychosis. Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors that are thought to play an important role in dementia-related psychosis.

ACADIA Pharmaceuticals

Company Details